An improved fermentation process for producing the Gram-positive antibiotic A47934 using a new strain of Streptomyes toyocaensis (NRRL 18112, culture A80934) is provided. The new strain is also particularly receptive toward certain useful plasmids.

The present invention is directed to a method for selectively enhancing the production of factors A, and/or B₀ of antibiotic A 40926 either to isolate these single components in better yields or to enrich the complex in one or both the above components, which comprises adding an appropriate precursor of the desired antibiotic factor to an A 40926 producing culture during fermentation.

Novel compounds, called mureidomycins A, B, C, and D, may be prepared by cultivation of a suitable microorganism of the genus Streptomyces, especially Streptomyces flavidovirens SANK 60486 (FERM P-8636. FERM BP-1347). These represent a wholly new class of antibiotics, which are valuable in the treatment of infections caused by a variety of bacteria, notably of the genus Pseudomonas.

A novel compound, called chloropolysporin, has antibiotic properties and would appear to be a member of the class of glycopeptide antibiotics containing chlorine. It may be produced by cultivating a suitable strain of microorganism of the genus Mecropolyspora, especially Micropolyspora sp. SANK 60983 (FERM BP-538). It may be combined with conventional pharmaceutically acceptable carriers or diluents for therapeutic use or incorporated into edible excipients, such as feed or water, for use as a growth-promoting agent, especially for farm animals.

Compounds CL-1577D and CL-1577E are prepared by cultivation of a purified isolate of Actinomycete designated ATCC 39363 in a culture medium having assimilable sources of carbon and nitrogen. The compounds are effective antimicrobial agents and possess cytotoxic activity against L1210 murine leukemia cells and P388 murine leukemia cells.

An antibiotic 6270 having the following physicochemical properties and a salt thereof:

• (1) Colorless needle-like crystals; acidic substance
• (2) Melting point: 115 - 118°C
• (3) Elementary analysis (Found %): C: 62.72%. H: 9.49%; 0: 27.78%
• (4) Specific rotation: [α]²⁰_D- 11.5° (C 1.0, methanol)
• (5) Ultraviolet absorption spectrum: The maximum absorption bands not observed at 210 nm or more. as measured in the methanol solution
• (6) Characteristic absorption (cm^-1) in the infrared absorption spectrum (taken with the potassium bromide tablet):
  • 3470. 2890, 2945, 2980, 1735, 1460, 1380, 1315, 1165, 1102, 1075, 987, 980
• (7) Solubility: Soluble in methanol ethanol, ethyl acetate, chloroform, ether, acetone, and benzene; insoluble in water
• (8) Color reactions: Positive in the vanilline-sulfuric acid reaction and the Dragendorff reaction; negative in the ninhydrin reaction; colors with 1₂ gas

A novel antibiotic complex of "vancomycin-like" antibiotics, AAD 216 complex, is produced by the cultivation of a fermentation broth containing Kibdelosporangium aridum Shearer gen. nov., sp. nov. ATCC 39323 microorganisms in an aqueous nutrient medium under submerged aerobic conditions. The AAD 216 complex and its major bioactive components; AAD 216A, AAD 216B, and AAD 216C exhibit antibiotic activity and growth promotant activity.

The present invention concerns a new antibiotic substance arbitrarily denominated antibiotic A 40926 complex and its factors antibiotic A 40926 factor A antibiotic A 40926 factor B. antibiotic A 40926 factor B_o, antibiotic A 40926 factor PA and antibiotic A 40926 factor PB, a process for producing them by culturing the new strain Actinomadura sp. ATCC 39727 or an A 40926 producing variant or mutant thereof and the use of these new antibiotic substances in the treatment of infectious diseases involving microorganisms susceptible to them. The antibiotic substances of the invention are glycopeptidic substances belonging to the vancomycin class or antibiotics which have binding capacity to Acyl-D-Alanyl-D-Alanine.

Novel antibiotic SF-2288 is produced by fermentation of an actinomycete belonging to the genus Actinomadura in nutrient medium. Based on its physico-chemical and biological properties, antibiotic SF-2288 possesses an excellent antimicrobial activity against Gram-positive and Gram-negative microorganisms and antiviral activity.

Antibiotic albicidin, a non-peptide antibiotic, is produced by culturing chlorosis-inducing strains of Xanthomonas albilineans isolated from diseased sugarcane, and mutants thereof. The antibiotic is isolated from the culture medium by adsorption on resin and is purified by gel filtration and HPLC.

This invention relates to a novel macromolecular tumor cell growth-inhibiting antibiotic; the microorganism which produces such antibiotic; a pharmaceutical composition comprising an effective, tumor cell growth inhibiting amount of such antibiotic and to its use in treating tumor cells in a host animal afflicted by such tumor cells.

@ The invention relates to a novel antibiotic 82-85-8A having antimicrobial and cell-cidal activity. This antibiotic is produced by a microorganism belonging to genus Streptomyces. The invention also concerns a production process thereof.

The present invention is directed to a class of basic monocarboxyamide derivatives of actagardine. Actagardine - (INN) is an antibiotic substance produced by actinoplanes strains such as Actinonplanes Sp. ATCC 31048 and Actinoplanes Sp. ATCC 31049 which are described in US patent 4,022,884. Actagardine shows antimicrobial in vitro and in vivoactivity against gram-positive organisms. Its complete chemical structure is not yet known but there is only information on its chemical functions and main fragments. In particular, it has been found that actagardine has two carboxylic functions and a primary amino function and can therefore be represented as follows:

The compounds of the invention are monoamide derivatives at one of the carboxy functions of actagardine. More particularly, they are basic monamide derivatives of actagardine which may be schematically represented by the following formula 1:

The compounds of the invention possess improved antimicrobial activity in particular against gram positive bacteria.

The present invention concerns a new antibiotic substance arbitrarily denominated antibiotic A 40926 complex and its factors antibiotic A 40926 factor A antibiotic A 40926 factor B. antibiotic A 40926 factor B_o, antibiotic A 40926 factor PA and antibiotic A 40926 factor PB, a process for producing them by culturing the new strain Actinomadura sp. ATCC 39727 or an A 40926 producing variant or mutant thereof and the use of these new antibiotic substances in the treatment of infectious diseases involving microorganisms susceptible to them. The antibiotic substances of the invention are glycopeptidic substances belonging to the vancomycin class or antibiotics which have binding capacity to Acyl-D-Alanyl-D-Alanine.

The present invention relates to novel agents, to their production by fermentation, to methods for their recovery and concentration from crude solutions, to processes for their purification and to pharmaceutically end pharmacologically-acceptable salts thereof. Also, this invention relates to methods and compositions for the control and prevention of helmintic, arthropod ectoparasitic and acaridal infections, in warm-blooded animals, such as meat-producing animals. and poultry. by administering to said animals a therapeutically or prophylactically-effective amount of new agents designated LL-F28249 α, β, γ, δ, ε, ζ, η, 6, , κ, λ, µ, v, and ω or mixtures thereof. The invention also relates to methods for the control of plant nematode infestations and other insecticidal activities. These novel agents are produced via a controlled condition microbiological fermentation using Streptomyces cyaneogriseus ssp. noncyanogenus, designated LL- F28249 and having deposited accession number NRRL 15773.